ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time

被引：168

作者：

Gerber, David E. ^{[1
,4
]}

Minna, John D. ^{[1
,2
,3
,4
]}

机构：

[1] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Hematol Oncol, Dallas, TX 75390 USA

[2] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA

[3] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA

[4] Univ Texas SW Med Ctr Dallas, Simmons Canc Ctr, Dallas, TX 75390 USA

来源：

CANCER CELL | 2010年 / 18卷 / 06期

关键词：

PHASE-III TRIAL; ANAPLASTIC LYMPHOMA; SOMATIC MUTATIONS; C-MET; KINASE; GENE; GENOME; IDENTIFICATION; AMPLIFICATION; PF-2341066;

D O I：

10.1016/j.ccr.2010.11.033

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

It was only 3 years ago that an acquired translocation of EML4 with ALK leading to the expression of an EML4-ALK oncoprotein in non-small cell lung cancer (NSCLC) was reported. Tumor cells expressing EML4-ALK are "addicted" to its continued function. Now, crizotinib, an oral ALK inhibitor, is demonstrated to provide dramatic clinical benefit with little toxicity in patients having such advanced NSCLC, and a mechanism of clinical resistance to crizotinib is identified. Such therapy "targeted" at oncogenic proteins provides "personalized" medicine and prompts genome-wide mutation analysis of human tumors to find other therapeutic targets.

引用

页码：548 / 551

页数：4

共 29 条

[1] Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor [J].

Butrynski, James E. ;

D'Adamo, David R. ;

Hornick, Jason L. ;

Dal Cin, Paola ;

Antonescu, Cristina R. ;

Jhanwar, Suresh C. ;

Ladanyi, Marc ;

Capelletti, Marzia ;

Rodig, Scott J. ;

Ramaiya, Nikhil ;

Kwak, Eunice L. ;

Clark, Jeffrey W. ;

Wilner, Keith D. ;

Christensen, James G. ;

Jaenne, Pasi A. ;

Maki, Robert G. ;

Demetri, George D. ;

Shapiro, Geoffrey I. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) :1727-1733

[2] Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment [J].

Camidge, D. Ross ;

Kono, Scott A. ;

Flacco, Antonella ;

Tan, Aik-Choon ;

Doebele, Robert C. ;

Zhou, Qing ;

Crino, Lucio ;

Franklin, Wilbur A. ;

Varella-Garcia, Marileila .

CLINICAL CANCER RESEARCH, 2010, 16 (22) :5581-5590

[3] Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer [J].

Choi, Young Lim ;

Takeuchi, Kengo ;

Soda, Manabu ;

Inamura, Kentaro ;

Togashi, Yuki ;

Hatano, Satoko ;

Enomoto, Munehiro ;

Hamada, Toru ;

Haruta, Hidenori ;

Watanabe, Hideki ;

Kurashina, Kentaro ;

Hatanaka, Hisashi ;

Ueno, Toshihide ;

Takada, Shuji ;

Yamashita, Yoshihiro ;

Sugiyama, Yukihiko ;

Ishikawa, Yuichi ;

Mano, Hiroyuki .

CANCER RESEARCH, 2008, 68 (13) :4971-4976

[4] EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors [J].

Choi, Young Lim ;

Soda, Manabu ;

Yamashita, Yoshihiro ;

Ueno, Toshihide ;

Takashima, Junpei ;

Nakajima, Takahiro ;

Yatabe, Yasushi ;

Takeuchi, Kengo ;

Hamada, Toru ;

Haruta, Hidenori ;

Ishikawa, Yuichi ;

Kimura, Hideki ;

Mitsudomi, Tetsuya ;

Tanio, Yoshiro ;

Mano, Hiroyuki .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) :1734-1739

[5] Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma [J].

Christensen, James G. ;

Zou, Helen Y. ;

Arango, Maria E. ;

Li, Qiuhua ;

Lee, Joseph H. ;

McDonnell, Scott R. ;

Yamazaki, Shinji ;

Alton, Gordon R. ;

Mroczkowski, Barbara ;

Los, Gerrit .

MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) :3314-3322

[6] The (r)evolution of cancer genetics [J].

Ciccarelli, Francesca D. .

BMC BIOLOGY, 2010, 8

[7] Somatic mutations affect key pathways in lung adenocarcinoma [J].

Ding, Li ;

Getz, Gad ;

Wheeler, David A. ;

Mardis, Elaine R. ;

McLellan, Michael D. ;

Cibulskis, Kristian ;

Sougnez, Carrie ;

Greulich, Heidi ;

Muzny, Donna M. ;

Morgan, Margaret B. ;

Fulton, Lucinda ;

Fulton, Robert S. ;

Zhang, Qunyuan ;

Wendl, Michael C. ;

Lawrence, Michael S. ;

Larson, David E. ;

Chen, Ken ;

Dooling, David J. ;

Sabo, Aniko ;

Hawes, Alicia C. ;

Shen, Hua ;

Jhangiani, Shalini N. ;

Lewis, Lora R. ;

Hall, Otis ;

Zhu, Yiming ;

Mathew, Tittu ;

Ren, Yanru ;

Yao, Jiqiang ;

Scherer, Steven E. ;

Clerc, Kerstin ;

Metcalf, Ginger A. ;

Ng, Brian ;

Milosavljevic, Aleksandar ;

Gonzalez-Garay, Manuel L. ;

Osborne, John R. ;

Meyer, Rick ;

Shi, Xiaoqi ;

Tang, Yuzhu ;

Koboldt, Daniel C. ;

Lin, Ling ;

Abbott, Rachel ;

Miner, Tracie L. ;

Pohl, Craig ;

Fewell, Ginger ;

Haipek, Carrie ;

Schmidt, Heather ;

Dunford-Shore, Brian H. ;

Kraja, Aldi ;

Crosby, Seth D. ;

Sawyer, Christopher S. .

NATURE, 2008, 455 (7216) :1069-1075

[8] Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor [J].

Ercan, D. ;

Zejnullahu, K. ;

Yonesaka, K. ;

Xiao, Y. ;

Capelletti, M. ;

Rogers, A. ;

Lifshits, E. ;

Brown, A. ;

Lee, C. ;

Christensen, J. G. ;

Kwiatkowski, D. J. ;

Engelman, J. A. ;

Jaenne, P. A. .

ONCOGENE, 2010, 29 (16) :2346-2356

[9] COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer [J].

Forbes, Simon A. ;

Tang, Gurpreet ;

Bindal, Nidhi ;

Bamford, Sally ;

Dawson, Elisabeth ;

Cole, Charlotte ;

Kok, Chai Yin ;

Jia, Mingming ;

Ewing, Rebecca ;

Menzies, Andrew ;

Teague, Jon W. ;

Stratton, Michael R. ;

Futreal, P. Andrew .

NUCLEIC ACIDS RESEARCH, 2010, 38 :D652-D657

[10] TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer [J].

Herbst, RS ;

Prager, D ;

Hermann, R ;

Fehrenbacher, L ;

Johnson, BE ;

Sandler, A ;

Kris, MG ;

Tran, HT ;

Klein, P ;

Li, X ;

Ramies, D ;

Johnson, DH ;

Miller, VA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5892-5899

← 1 2 3 →